Immuneering Corp Stock Price, News & Analysis

Immuneering (NASDAQ: IMRX) reported its Q1 2025 financial results and provided significant clinical updates. The company highlighted impressive results for IMM-1-104 in pancreatic cancer treatment, including a third-line monotherapy patient with over 13 months progression-free survival and a first-line combination therapy patient achieving complete response. The company's financial position shows $35.9 million in cash as of March 31, 2025, with runway extended into 2026. Q1 net loss was $15.0 million ($0.42 per share). Key developments include appointing Dr. Igor Matushansky as CMO and establishing a clinical trial agreement with Regeneron to evaluate IMM-1-104 with Libtayo in non-small cell lung cancer. The company plans to announce progression-free survival data from over 30 first-line pancreatic cancer patients in Q2'25 and initiate a Phase 3 trial in 2026.

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference scheduled for April 7-10, 2025. The company's management team will deliver a presentation on April 9, 2025, from 1:30 - 2:10 pm ET.

The presentation will feature key executives including CEO Ben Zeskind, CSO Brett Hall, CMO Igor Matushansky, CBO Harold Brakewood, CLO Michael Bookman, and CAO Mallory Morales. They will discuss Immuneering's pipeline, platform, and business strategy. The event will include both a company presentation and one-on-one investor meetings.

Interested parties can access the live webcast and archived recording through the Investor Relations section of Immuneering's website under Events & Presentations.

Immuneering (Nasdaq: IMRX) has granted an inducement stock option award to its newly appointed Chief Medical Officer, Dr. Igor Matushansky. The award, issued on March 21, 2025, consists of options to purchase 118,000 shares of Class A common stock at an exercise price of $1.80 per share, matching the closing price on Nasdaq Global Market that day.

The stock option, granted under the company's 2025 Employment Inducement Award Plan and approved by the Board of Directors, has a ten-year term. The vesting schedule includes 25% vesting on March 17, 2026, with the remaining 75% vesting in monthly installments over the following three years, achieving full vesting by March 17, 2029. The grant was made under Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Immuneering (NASDAQ: IMRX) has reported promising results from its Phase 2a trial of IMM-1-104 in pancreatic cancer combinations. The drug showed a 43% objective response rate (ORR) when combined with modified gemcitabine/nab-paclitaxel and 50% ORR with modified FOLFIRINOX, significantly exceeding historical benchmarks of 23% and 32% respectively.

The company highlighted a notable case study of a Phase 1 pancreatic cancer patient maintaining stable disease for over 13 months on IMM-1-104 monotherapy, with a 91% reduction in CA 19-9 levels. Immuneering secured a clinical trial agreement with Regeneron to evaluate IMM-1-104 with Libtayo in non-small cell lung cancer.

Financial results show cash position of $36.1 million as of December 31, 2024, with an additional $13.7 million raised in January 2025. The company reported a net loss of $61.0 million for full year 2024. Cash runway is expected to extend into 2026.

Immuneering (IMRX) has appointed Dr. Igor Matushansky as Chief Medical Officer to lead their clinical activities. Dr. Matushansky will oversee the ongoing Phase 2a study of IMM-1-104 in pancreatic cancer, lung cancer, and melanoma, as well as plans for a pivotal Phase 3 trial in pancreatic cancer.

The company plans to present updated data from the Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025. Earlier Phase 2a data from January showed promising results for first-line pancreatic cancer patients, suggesting improved efficacy and tolerability compared to standard care.

Dr. Matushansky brings extensive oncology experience from previous roles at Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma, and Daiichi Sankyo. At Ipsen, he oversaw the NAPOLI-3 trial that led to NALIRIFOX's approval for first-line pancreatic cancer treatment.

Immuneering (NASDAQ: IMRX) has announced a clinical supply agreement with Regeneron Pharmaceuticals to evaluate its lead product candidate IMM-1-104 in combination with Regeneron's anti-PD-1 therapy, Libtayo (cemiplimab). The combination will be tested in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC) as part of Immuneering's ongoing Phase 2a clinical trial.

This marks Immuneering's first collaboration involving IMM-1-104. Under the agreement terms, Immuneering will sponsor the studies while Regeneron provides Libtayo. Immuneering retains global development and commercialization rights to IMM-1-104. The collaboration is supported by preclinical data presented at AACR 2023, which demonstrated the dual-targeting potential of IMM-1-104 in combination with immuno-oncology agents to break tumor MAPK addiction and enhance anti-tumor immunity.

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual conference is scheduled for February 11-12, 2025.

The company's management team, including Chief Executive Officer Ben Zeskind and Chief Scientific Officer Brett Hall, will deliver a presentation on February 12 from 2:40 – 3:10 pm ET in Track 2. During the conference, they will discuss Immuneering's pipeline, platform, and business strategy.

The presentation will be accessible through a live webcast and will be archived in the Investor Relations section of Immuneering's website under Events & Presentations.

Immuneering (Nasdaq: IMRX) has announced positive updates from its Phase 2a clinical trial evaluating IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first-line pancreatic cancer. The trial reported two new partial responses (PRs), resulting in an overall response rate (ORR) of 50%, surpassing the historic benchmark of 32% for FOLFIRINOX alone. As of January 6, 2025, six patients were evaluable, with three achieving partial responses.

The combination therapy was generally well tolerated. Immuneering raised nearly $14 million in net proceeds through its ATM facility, enhancing its cash balance. The company plans to provide further Phase 2a data in the second quarter of 2025 and to initiate new trial arms combining IMM-1-104 with a BRAF inhibitor and a checkpoint inhibitor. Additionally, planning for a pivotal trial of IMM-1-104 with modified gemcitabine/nab-paclitaxel is underway.

Immuneering (NASDAQ: IMRX) reported positive data from three pancreatic cancer arms of its Phase 2a trial for IMM-1-104. The drug showed a 43% overall response rate (ORR) and 86% disease control rate (DCR) when combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients.

Initial data for IMM-1-104 with modified FOLFIRINOX in first-line pancreatic cancer showed tumor shrinkage in all evaluable patients, including a 100% reduction. In second-line pancreatic cancer monotherapy, the drug demonstrated a 67% reduction in one patient.

The company plans to expand the trial with three additional combination arms in 2025, including combinations with BRAF inhibitor in melanoma and immune checkpoint inhibitors in both melanoma and NSCLC. Further Phase 2a data is expected in Q2 2025.